UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Ltd., a biotech company focused on urothelial and specialty cancers, announced it will participate in key healthcare investor conferences in September 2026, including Wells Fargo, Cantor Global, and H.C. Wainwright events. Presentations will be webcast and available for replay on the company's website.

URGN

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

UroGen will participate in three major healthcare investor conferences in September 2026, presenting via fireside chats.
Company highlights its proprietary RTGel sustained-release hydrogel technology and approved products targeting urothelial cancers.
Webcasts of presentations will be accessible on the company's investor relations site, providing transparency and engagement with investors.

PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September.

Wells Fargo 21st Annual Healthcare Conference

Date / Time:September 9th, at 3:00 PM ETFormat:Fireside ChatLocation:Boston, MAWebcast Link:Here

Cantor Global Healthcare Conference 2026

Date / Time:September 10th, at 2:10 PM ETFormat:Fireside ChatLocation:New York, NYWebcast Link:Here

H.C. Wainwright 28th Annual Global Investment Conference

Date / Time:September 15th, at 9:00 AM ETFormat:Fireside ChatLocation:New York, NYWebcast Link:Here

The webcasts from the conference will also be available on UroGen’s Investor Relations website. A replay will be available for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is approved for adult patients with recurrent LG-IR-NMIBC. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
[email protected]
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
[email protected]
609-460-3566 ext. 1083

Risks

The article does not disclose any new clinical data or regulatory updates, so near-term impact on product commercialization remains uncertain.
Investor conferences can generate interest but do not guarantee financing or sales growth, leaving commercial success dependent on market adoption.
Biotech sector risks remain including clinical trial outcomes and competitive therapeutic developments that could influence UroGen's future prospects.

Menu

UroGen Pharma to Present at Upcoming Investor Conferences

Key Points

Risks

More from Press Releases